Reports published by Fact.MR and Future Market Insights project that the global market could expand from approximately $2.6 billion in 2026 to $6.7 billion by 2036, with an estimated compound annual growth rate of around 10%. 

The analyses attribute this growth to rising demand for minimally invasive procedures that support long-term skin quality and tissue regeneration, rather than immediate volumisation alone. Treatments highlighted include PLLA-based collagen stimulators, calcium hydroxyapatite biostimulators, autologous regenerative therapies and energy-based collagen induction technologies. 

PLLA-based products were identified as the leading category within the market, while facial rejuvenation and skin quality improvement remain the most common treatment indications globally. The reports also highlighted increasing interest in personalised treatment planning, combination regenerative protocols and AI-supported skin assessment technologies. 

North America currently represents the largest market, while Asia-Pacific is forecast to experience the fastest growth over the next decade.